Korea Reviews MFDS Oversight for Human Tissue Skin Boosters
21. May 2026South Korea is moving to strengthen oversight of human tissue-derived cosmetic injectables as concerns grow over safety, ethics, and regulatory consistency in the rapidly expanding aesthetic medicine sector. The debate has intensified around extracellular matrix (ECM) skin booster products, which are currently distributed under a separate human tissue management framework rather than through the conventional MFDS medical device approval pathway.
Industry experts, consumer groups, and regulators recently discussed the issue during a biohealth policy forum held at the National Assembly in Seoul. Participants highlighted what they described as a regulatory gap that allows some human tissue-based medical products to enter the Korean market without undergoing clinical trials, product-level approval, or formal adverse event monitoring systems.
Medical products usually require MFDS certification in order to be approved for import and sale in Korea.
Human Tissue Cosmetic Products Face Regulatory Scrutiny
The controversy centers on ECM skin booster products manufactured from cadaver skin tissue donated by deceased individuals. The tissue is processed into extracellular matrix material, diluted, and injected directly into the skin during cosmetic dermatology procedures. Despite functioning similarly to injectable medical products, these materials are currently regulated as “human tissue” rather than as pharmaceuticals or medical devices.
Critics argue that this classification creates uneven regulatory standards compared with approved Class IV medical devices such as Rejuran and Juvelook, which reportedly underwent extensive clinical testing and MFDS review before commercialization. By contrast, certain ECM-based products have entered the market without equivalent approval procedures because they fall under human tissue regulations.
Consumer advocacy groups have also raised concerns regarding patient safety and informed consent. They argue that products injected into the human body should meet the same standards for efficacy verification, safety monitoring, and adverse event reporting as other injectable medical technologies.
In addition to safety concerns, ethical questions surrounding donor intent have become a major focus. Human tissue donation systems were originally established to support therapeutic applications such as wound healing and burn treatment. Critics contend that using donated tissue for premium cosmetic procedures may conflict with the intended purpose of tissue donation programs.
Government Considers Stronger MFDS and Welfare Ministry Controls
South Korean authorities are now reviewing supplementary regulatory measures. Discussions reportedly include stronger labeling and advertising restrictions, enhanced adverse event reporting systems, and tighter controls over intended product use by tissue banks.
Officials from both the Ministry of Health and Welfare and the Ministry of Food and Drug Safety (MFDS) acknowledged that the current legal framework lacks direct mechanisms for regulating cosmetic applications of human tissue products. Authorities also indicated that legislative discussions are underway with lawmakers to determine the appropriate scope of future oversight.
International regulatory practices are also influencing the debate. In the United States and Europe, human tissue-derived products are generally subject to stricter conditions regarding manipulation, homologous use, quality control, and premarket review. Korean regulators are therefore facing growing pressure to align domestic management standards more closely with overseas practices.
The expanding regenerative medicine sector is expected to remain a key factor in future regulatory reforms as South Korea evaluates how to balance innovation, patient safety, and ethical standards for human tissue-based medical products.
Feel free to contact us any time if you need assistance or have any questions regarding Korean certifications like KC, KC EMC, KCs, KCs for explosion safety products, KGS factory registration and MFDS for medical devices.
Tel. Europe: +49-69-271 37 69 259
Tel. US: +1 773 654-2673
Email: info@korea-certification.com
For more information you can download our free brochure “Korea Certification Made Easy – The Booklet“.
